Allo-MM-PostCy-Study (#763)
Laufzeit: 01.01.2018 - 31.12.2040
imported
Kurzfassung
Cyclophosphamide as graft-versus-host prophylaxis after allogeneic stem cell transplantation for multiple myeloma. A phase II study.
Laufzeit: 01.01.2018 - 31.12.2040
Cyclophosphamide as graft-versus-host prophylaxis after allogeneic stem cell transplantation for multiple myeloma. A phase II study.